These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 22571789)

  • 1. Insights from structural analysis of cFMS/inhibitor complexes: common interactions via three structurally dissimilar scaffolds.
    DesJarlais RL
    Curr Top Med Chem; 2012; 12(11):1271-81. PubMed ID: 22571789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors.
    Schubert C; Schalk-Hihi C; Struble GT; Ma HC; Petrounia IP; Brandt B; Deckman IC; Patch RJ; Player MR; Spurlino JC; Springer BA
    J Biol Chem; 2007 Feb; 282(6):4094-101. PubMed ID: 17132624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
    Pathak D; Chadha N; Silakari O
    J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.
    Suárez RM; Chevot F; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
    Eur J Med Chem; 2013 Mar; 61():2-25. PubMed ID: 22749189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist.
    Baladi T; Abet V; Piguel S
    Eur J Med Chem; 2015 Nov; 105():220-37. PubMed ID: 26498569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors.
    Schlütke L; Immer M; Preu L; Totzke F; Schächtele C; Kubbutat MHG; Kunick C
    Eur J Pharm Biopharm; 2018 May; 126():89-94. PubMed ID: 28315448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.
    Ravichandran S; Luke BT; Collins JR
    J Mol Graph Model; 2015 Apr; 57():36-48. PubMed ID: 25635590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
    Cao H; Zhang H; Zheng X; Gao D
    J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.
    James N; Ramanathan K
    Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
    Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
    Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain.
    Bagal SK; Andrews M; Bechle BM; Bian J; Bilsland J; Blakemore DC; Braganza JF; Bungay PJ; Corbett MS; Cronin CN; Cui JJ; Dias R; Flanagan NJ; Greasley SE; Grimley R; James K; Johnson E; Kitching L; Kraus ML; McAlpine I; Nagata A; Ninkovic S; Omoto K; Scales S; Skerratt SE; Sun J; Tran-Dubé M; Waldron GJ; Wang F; Warmus JS
    J Med Chem; 2018 Aug; 61(15):6779-6800. PubMed ID: 29944371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA-approved small-molecule kinase inhibitors.
    Wu P; Nielsen TE; Clausen MH
    Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New aminopyrimidine derivatives as inhibitors of the TAM family.
    Traoré T; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
    Eur J Med Chem; 2013; 70():789-801. PubMed ID: 24239626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
    Li Y; Lu X; Ren X; Ding K
    J Med Chem; 2015 Apr; 58(8):3287-301. PubMed ID: 25569119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK).
    Tu CH; Lin WH; Peng YH; Hsu T; Wu JS; Chang CY; Lu CT; Lyu PC; Shih C; Jiaang WT; Wu SY
    J Med Chem; 2016 Apr; 59(8):3906-19. PubMed ID: 27031565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors.
    Zhou S; Li Y; Hou T
    J Chem Inf Model; 2013 Apr; 53(4):982-96. PubMed ID: 23506306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
    Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
    J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping Biological Activities to Different Types of Molecular Scaffolds: Exemplary Application to Protein Kinase Inhibitors.
    Dimova D; Bajorath J
    Methods Mol Biol; 2018; 1825():327-337. PubMed ID: 30334211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.